These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 29798688)

  • 1. Thirteen-year trend in the persistence with vitamin K antagonists for venous thromboembolism in the UK: a cohort study.
    Martinez C; Katholing A; Folkerts K; Rietbrock S
    Curr Med Res Opin; 2018 Nov; 34(11):1985-1990. PubMed ID: 29798688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
    Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
    Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.
    Jiménez D; Díaz G; Marín E; Vidal R; Sueiro A; Yusen RD
    Thromb Haemost; 2006 Mar; 95(3):562-6. PubMed ID: 16525588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism.
    Kovacs MJ; Kahn SR; Wells PS; Anderson DA; Chagnon I; LE Gal G; Solymoss S; Crowther M; Perrier A; Ramsay T; Betancourt MT; White RH; Vickars L; Rodger MA
    J Thromb Haemost; 2010 Sep; 8(9):1926-32. PubMed ID: 20561184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
    Kyrle PA; Kammer M; Eischer L; Weltermann A; Minar E; Hirschl M; Heinze G; Eichinger S
    J Thromb Haemost; 2016 Dec; 14(12):2402-2409. PubMed ID: 27696701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Ageno W; Casella IB; Han CK; Raskob GE; Schellong S; Schulman S; Singer DE; Kimura K; Tang W; Desch M; Goldhaber SZ
    Thromb Haemost; 2017 Jan; 117(2):415-421. PubMed ID: 27853808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism.
    Gabara C; Aibar J; Nishimoto Y; Yamashita Y; Prandoni P; Barnes GD; Bikdeli B; Jiménez D; Demelo-Rodríguez P; Peris ML; Nguyen ST; Monreal M;
    J Thromb Haemost; 2024 Aug; 22(8):2234-2246. PubMed ID: 38762019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated.
    Kearon C
    J Thromb Thrombolysis; 2011 Apr; 31(3):295-300. PubMed ID: 21331558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ
    Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin therapy associated with improved thrombus resolution in patients with deep vein thrombosis.
    Hsu C; Brahmandam A; Brownson KE; Huynh N; Reynolds J; Lee AI; Fares WH; Ochoa Chaar CI
    J Vasc Surg Venous Lymphat Disord; 2019 Mar; 7(2):169-175.e4. PubMed ID: 30660579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
    Haas S; Ageno W; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Dalsgaard Nielsen J; Kayani G; Zaghdoun A; Farjat AE; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK
    J Thromb Haemost; 2019 Oct; 17(10):1694-1706. PubMed ID: 31220403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
    Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case-control study.
    Martinez C; Katholing A; Folkerts K; Cohen AT
    J Thromb Haemost; 2016 Jul; 14(7):1374-83. PubMed ID: 27079164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
    Cohen AT; Gitt AK; Bauersachs R; Fronk EM; Laeis P; Mismetti P; Monreal M; Willich SN; Bramlage P; Agnelli G; Prefer In Vte Scientific Steering Committee And The Prefer In Vte Investigators OBOT
    Thromb Haemost; 2017 Jun; 117(7):1326-1337. PubMed ID: 28405675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort.
    Tagalakis V; Patenaude V; Kahn SR; Suissa S
    Thromb Res; 2014 Oct; 134(4):795-802. PubMed ID: 25135794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.